secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orchestra BioMed Holdings, Inc. (OBIO)
CIK:        0001814114
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001104659-25-040763
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orchestra BioMed gets FDA Breakthrough Device Designation for AVIM therapy and IDE approval for Virtue SAB trial
--------------------------------------------------------------------------------

- FDA granted Breakthrough Device Designation for AVIM therapy; covers >7.7M U.S. hypertension patients.
- AVIM therapy BDD may expedite FDA review and support higher reimbursement (NTAP/TPT).
- FDA approved IDE amendment for Virtue SAB randomized trial vs AGENT paclitaxel DCB for coronary ISR.
- Virtue Trial plans 740 patients across 75 U.S. centers; targeting H2 2025 start.
- Virtue SAB pilot showed 12-month TLF 2.8% and 6-month late lumen loss 0.12mm.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1814114/000110465925040763/0001104659-25-040763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1814114/000110465925040763/tm2513456d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-040763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer